Fulgent Genetics, Inc. Class Action Lawsuit - FLGT

(i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the FLGT class action lawsuit, you must have incurred a loss on shares of Fulgent purchased during the class period listed above.

If you suffered a loss in Fulgent during the relevant time frame or pursuant to the relevant offering(s), you have until November 21, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.